Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The Lancet. Oncology|July 21, 2009
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialMartin E Gore, Cezary Szczylik, Camillo Porta, et al.Journal of Clinical Pharmacology|February 9, 2008
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteersCarol Addy, Susie Li, Nancy Agrawal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinomaRobert J Motzer, Thomas E Hutson, Mark R Olsen, et al.Journal of Clinical Pharmacology|May 30, 2008
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteersCarol Addy, Paul Rothenberg, Susie Li, et al.JAMA|December 6, 2016
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical TrialHope S Rugo, Abhijit Barve, Cornelius F Waller, et al.Cell Metabolism|January 8, 2008
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intakeCarol Addy, Hamish Wright, Koen Van Laere, et al.Pageof 2